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Ancient civilization to present-day cultural and technological development, human over the world has been using plants 
as a source of natural medicine for their basic needs. Clerodendrum serratum (Linn.) Moonis one such traditionally well-
accepted plant used vigorously in Indian ayurvedic therapeutic purposes. Despite its ethnomedicinal significance, the 
neuroprotective prospects and relevance of Clerodendrum serratum (CSL) remain unaddressed. Therefore, in the present 
study, we explored several in-vivo antioxidant enzymatic assays followed by acetylcholinesterase enzyme (AChE) inhibitory 
activity against neurodegenerative disorders (NDs) in mice model and explore the beneficial impact of the plant extract. 
Furthermore, the in-silico molecular docking approach was employed to evaluate the inhibitory potential of the plant-
derived bioactive compounds against the imperative proteins associated with neurodegenerative disorders. The plant extract 
showed promising results in all in-vivo enzymatic assays indicating its positive role over several neurodegenerative 
disseases namely, Alzheimer’s and Parkinson’s disease. The histological and in-silico investigation also reveled this plant 
extract is promising in elevating neurodegenerative disorders. Therefore, it seems likely that this plant can be used as an 
anti-cognitive agent for future drug development. 
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Every culture all over the world has been using plants 
for natural medicine and depends on nature for their 
existence since ancient times. The therapeutic 
relevance of medicinal plants in India has led to 
extensive exploration of their medicinal attributes1-3. 
Several phytocompounds including tannins, alkaloids, 
steroids, phenols and flavanoids find widespread 
applications in treating various ailments4. The 
phytocompounds nullify the oxidative stress in the 
human body rendering immunity against chronic 
diseases. Different neurodegenerative disorders (NDs) 
like dementia, Alzheimer’s disease (AD) and 
Parkinson’s disease (PD)5,6 are caused by reactive 
oxygen and nitrogen species as consequences of 
oxidative stress. It has been reported that 
neurodegenerative disorders can be balanced by the 
antioxidative defense system7.  
Clerodendrum serratum (Linn.) Moon, a semi-
woody shrub, locally known as ‘Bharangi’ belonging 
to Lamiaceae family, is found in some parts of Asia 
and Africa. Ethnomedicinally, C. serratum is chiefly 
used for respiratory diseases viz. colds, bronchitis, 
bronchial asthma and tuberculosis8. Water decoction 
of C. serratum is used as a remedy to high blood 
pressure in Malayasia9. In the Indian traditional 
system of therapeutics, the plant was mentioned as an 
important ingredient of several Ayurvedic 
preparations like Dashmoolarishtha (a health tonic, 
prepared from the roots of 10 medicinal species), 
Chavanprasha (used to treat fever, asthma, anorexia 
and stomachache) and Panchatikta ghrita guggul 
(prescribed for a neurological disorder, herpes, 
inflammation and arthritis) to treat regular ailments10. 
Reviews on Clerodendrum serratum reported 
preliminary antioxidant, antibacterial and anti-
inflammatory activities11,12. 
Quite surprisingly, no major step has still been 
carried out to validate the neuroprotective relevance 
of Clerodendrum serratum (CSL). In our previous 
reports, we have successfully been justified the 
ethnomedicinal claims of Hippophae salicifolia6. 
Therefore, an initiative was undertaken to analyze a 
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detailed neuroprotective effect of CSL in mice 
models. In this regard, the neurotherapeutic activity of 
Clerodendrum serratum leaf (CSL) was executed in 
the present study using different in-vivo antioxidant 
methods as well as in-silico molecular docking 
analysis justifying its beneficial effects over oxidative 
stress. 
 
Materials and Methods 
Plant material 
C. serratum (CSL) leaves were collected during 
April and May 2017, from Azra, Guwahati, Assam 
(26.1445° N, 91.7362° E).  
 
Preparation of plant extracts 
A mechanical grinder was used to pulverize air-
dried (3 weeks) disease-free fresh leaves of C. 
serratum into a fine powder. The crushed leaves of 
CSL (10 g) were extracted in 70% methanol (v/v) for 
6-7 hours using soxhlation procedure. Rotary 
evaporator was used to concentrate the extract. 
Finally, the extract was lyophilized to obtain dry 
powder for further use.  
 
Animals and care 
In this experiment, inbreed male Swiss albino mice 
(8-9 weeks age and 34±2gms body weight) were kept 
in polypropylene cage (6 male mice/group, n=6) in 
the animal house with food and water. Throughout the 
experiment a constant temperature (25 ±2 °C) and 
humidity (55±5 %) was maintained. 
 
Acute toxicity analysis 
The acute toxicity of CSL extract was assessed 
following OECD guidelines. Animals were divided 
into five groups (n=6). The plant extract was fed 
orally with increasing concentrations (250, 500, 1000, 
and 2000 mg/kg body weight) to the mice. 
Subsequently, all the groups were methodically 
monitored to note the development of toxicological 
symptoms at different time interval. 
 
Experimental setup and administration of the dose 
The animals (30 male mice) were divided into five 
groups and this treatment was carried out daily for 7 
days: 
Group I: Control, received normal saline water; 
Group II: Scopolamine group received Scopolamine 
(0.5 mg/kg/day BW) intraperitonially; Group III: 
Donepezil group received scopolamine (0.5mg/kg/day 
BW) and donepezil (10 mg/kg/day BW); Group IV: 
Mice received scopolamine (0.5 mg/kg/day BW) and 
low dose extract of CSL at 100 mg/kg/day BW; 
Group V: Mice received scopolamine (0.5 mg/kg/day 
BW) and high dose extract of CSL at 400 mg/kg/day 
BW respectively. On the 8th day, plant 
extracts/standard drug/normal saline was 
administrated orally after 90 min. of scopolamine 
treatment followed by behavioral tests performed 
after 45 min of injection. At 9th day of the last 
injection the behavioral test was performed to 
measure the retention time. All the trial and 
examining sessions were carried out at night, 
preferably between 19:00 and 23:00 h due to the 
restless movement of the mice at night.  
 
Passive avoidance task 
The methods of Reddy13 was employed to study the 
passive avoidance task. 
 
Preparation of brain tissue samples 
After behavioral evaluations, the animals were 
sacrificed (2% mild ether) by cervical dislocation. The 
brain of the sacrificed mice of each group were removed 
quickly from the skull and washed consciously in ice 
cold normal saline. Subsequently, homogenization was 
performed using phosphate buffer (50mM; pH 7.4), 
potassium chloride (KCl; 120mM), and finally BHT 
(0.004%, w/v) was added to prevent auto-oxidation of 
the samples. Centrifugation was performed at 3000 rpm 
for 10 min at 4ºC.  
 
In-vivo brain enzymatic assays 
Acetylcholinesterase inhibiting activity (AChE), 
DPPH, Catalase (CAT), Reduced Glutathione (GSH), 
Superoxide dismutase (SOD) activity and MDA 




Mice brains were removed and were fixed in 10% 
formaldehyde solution. The method opted by  
Knodell et al.15 was used to prepare, stain and cut the 
brain sections.  
 
GC-MS analysis 
GC-MS analysis was conducted as perthe standard 
protocol with slight modifications. 
 
Molecular Docking 
The major compounds present in CSL were used 
for the purpose of molecular docking analysis against 
dopamine receptor D3 protein (PDB ID- 3PBL). The 
protein structure was retrived from the Protein Data 
Bank. The AutoDockVina16 software was employed to 




perform the molecular docking as per the scheme 
opted by Dutta et al.14. 
 
Statistical analysis 
Dunnett’s test implemented in KyPlot software 
(version 5.0) was employed to perform one-way 
analysis of variance (ANOVA) statistical test with a 
significance level at P< 0.05. 
 
Results and Discussion 
Acute toxicity study 
At high dose of CSL extract (2000 mg/kg), no 
death was observed in the mice. Therefore, in  
the present study 1/20th (100 mg/kg) and 1/5th  
(400 mg/kg) were considered safe for in-vivo studies.  
 
Body weight changes 
Table 1 depicts the mice body weight of the 
different groups and no significant weight gain was 
observed during this experiment. 
 
Passive avoidance test 
The present study accounted for an inclusive report 
of the neurotherapeutic effect of CSL on memory 
deficits in a mouse model of amnesia (passive 
avoidance test) scopolamine treatment. The fear-
motivated avoidance test was used to study the animal 
behavioral changes in presence of an unplesant 
stimulus (electric foot-shock) as a part of long-term 
memory. Table 2 revealed that the initial latency time 
to enter the dark chamber was significantly longer in 
the mice given only scopolamine as compared to the 
control group suggesting the amnesic effect of  
mice. The treatment with CSL extract 
significantlyattenuated the scopolamine-induced 
memory deficit in mice to a great extent and also 
associated with the short-term memory (STL) 
improvement (Table 2) suggesting the anti-amnesic 
effect of extracts in the scopolamine-induced rodent 
model. While considering brain AChE inhibitory 
activity, CSL extract increased the cholinergic activity 
to reverse the memory impairment in mice (Fig. 1A). 
Hence, it can be inferred that CSL could be a potent 
AChE-inhibitors by hindering the destruction of 
Ach17,18.  
 
In-vivo antioxidant assays 
In this experiment, scopolamine treatment 
significantly reduced the antioxidant capacity of 
DPPH, enzymatic catalase and SOD (superoxide 
dismutase) (Fig. 1B, 1D, 1F) and non-enzymatic 
reduced glutathione (GSH) system in brain tissues 
(Fig. 1E). At the same time, CSL treatment 
significantly increased the percent of inhibition of 
DPPH, catalase, SOD, and reduced glutathione when 
compared with scopolaminegroups. Figure 1C 
illustrates MDA or Lipid peroxidation level in the 
treated groups. The MDA content increased from 
28.26 ± 2.89mM/litre (in control) to 51.89 ± 5.17 
mM/litre in the scopolamine group. The increased 
MDA level was lowered to 32.93 ± 3.98mM/litre after 
a high dose of CSL administration significantly. 
Hence, the results suggest the anti-oxidative potential 
of CSL that contributed to effective neuronal 
plasticity and memory function. Thus, most 
importantly, we provide the first evidence for a potent 
neurotherapeutic role of CSL in the protection from 
ROSmediated neuronal damage as well as we 
identified some of the responsible target 
phytocompounds that could be treated as future CNS 
drug. It has been well speculated that every cellular 
organism sustains its own antioxidant stability to 
protect tissues from oxidative damage at a certain 
stage. SOD, catalase, GSH, etc. are the fundamental 
antioxidant enzymes that protect tissues from highly 
reactive hydroxyl radicals and superoxide anions, 
linked with NDs19,20. 
 
Histopathological examination 
The normal structure of the cerebral cortex  
and   hippocampus   in   control   mice  is  shown  by  
Table 1 — Effects of Clerodendrum serratum on the body  
weight of the treated mice 
 Initial Weight Final Weight % body weight 
change 
Control 34.35±1.07 36.45±2.03 NS 5.67±2.37▲ 
Scopolamine 36.95±1.34 32.71±1.86** 11.51±1.79▼ 
Donepezil 35.57±1.26 36.93±1.63NS 3.63±1.99▲ 
CSL Low 32.78±1.47 35.41±0.90NS 7.43±3.03▲ 
CSL High 33.68±1.96 35.43±1.67* 4.98±1.16▲ 
Weight (mean ± SD) in gram, * P<=0.05, ** P<=0.01, NS = Non
significant. Final body weight was compared with the initial body




Table 2 — Effect of CSL extract on scopolamine-induced 
memory impairment in the passive avoidance test 
Groups IL (Sec.) STL (Sec.) 
Group I (Control) 18.13±1.99 132.41±8.29 
Group II (SCP) 107.23±4.83 80.14±1.33 
Group III (SCP + Donepezil) 27.12±2.19 176.79±2.19 
Group IV (SCP + CSL low) 57.78±4.34 130.24±0.83 
Group V (SCP + CSL high) 35.66±2.39 165.23±1.45 
IL- Initial latency; STL- Step-Through Latency; SCP-
Scopolamine [Data represented as mean ± SD]. 










Fig. 2 — Photomicrograph of mice brain (cortex, A-E), 40X.  
(A) Normal neurons, glial cells are shown in control mice.  
(B) Chromatolysis (arrows), Gliosis, and edema in cortex shown in 
Scopolamine induced mice. (C) Donepezil exposure on mice brain 
showing less necrotic (arrows). (D) CSL extract (100mg/kg BW) 
showing marked gliosis (arrows). (E) CSL extract (400mg/kg BW) 
showing moderate necrotic and degenerative changes. 
 
histopathological sections (Fig. 2A and 3A). Mice 
with scopolamine exposure showed severe gliosis, 
edema,and chromatolysis (arrows) in the cortex  
(Fig. 2B), whereas, the hippocampus revealed severe 
necrotic   Purkinje  neurons   and   chromatolysis   of  
 
 
Fig. 3 — Photomicrograph of mice brain (Hippocampus region, 
A-E), 40X. (A) Normal glial cell layer and Purkinje layer shown 
in control mice. (B) Chromatolysis of nuclear material (arrows) 
and Purkinje neurons are shown in Scopolamine induced mice. 
(C) Donepezil exposed mice shows reduced severity of necrotic 
(arrows) and degenerative lesions. (D) Necrotic degeneration is 
shown by CSL extracts (1000mg/kg BW) on Purkinje neurons and 
lysis of glial cells (arrows). (E) Significantly less necrotic 
degeneration is shown by CSL extract (400mg/kg BW) on 
Purkinje neurons and lysis of glial cells (arrows).  
 
nuclear material (Fig. 3B). Mice brain exposed to 
donepezil showed less necrotic, degenerative changes 
with normal neurons and glial cells in both the cortex 
and hippocampus region (Fig. 2C and 3C). In the 
present study, the injury was down-regulated by a 




high dose of CSL extract (400 mg/kg BW) compared 
to the standard donepezil (Fig. 2E and 3E). 
 
GC-MS analyses 
The phytocompounds hexadecanoic acid, phytol, 
linoleic acid, oleic acid, squalene and stigmasterol 
were identified in CSL21 among which linoleic acid, 
oleic acid, squalene and stigmasterol were noted to be 
the main bioactive compounds.  
 
Molecular Docking 
The phytochemicals hexadecanoic acid, phytol, 
linoleic acid, oleic acid, squalene and stigmasterol 
revealed binding energy scores of -3.6, -4.4, -2.9, -
3.3, -5.7 and -6.1 kcal/mol respectively. It was 
interesting to note that stigmasterol displayed decent 
binding inhibition potential with the dopamine 
receptor D3 protein (Fig. 4). 
 
Conclusion 
The present study is the first ever detailed 
neuroprotective evaluation of ethnomedicinal plant 
Clerodendrum serratum. Despite of having massive 
ethnomedicinal utilization, proper clinical study of 
CSL was not yet executed. Hence, we intended to 
explore its different therapeutic applications in the 
present study. Results reflected that CSL was found to 
be a potent neuroprotective agent with non-toxic 
nature. In addition, CSL was first time assigned as 
AChEI over neurodegeneration as per the authors’ 
best knowledge. Therefore, it seems likely that this 
plantcan be used as an anti-cognitive agent for future 
drug development in AD and PD. 
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